Prevention of cervical cancer: Challenges and perspectives of hpv prophylactic vaccines

Emerging Issues on HPV Infections: From Science to Practice

Volumn , Issue , 2006, Pages 184-205

  Monsonego, Joseph ^a  

^a EUROGIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750393027     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000092755     Document Type: Chapter

References (52)

1. Syrjanen K, Syrjanen S.: Papillomavirus Infections in Human Pathology. Chichester, Wiley and Sons, 2000, pp 1-615.
2. Patnick J.: Screening that failed to work; in Franco E, Monsonego J (eds): New Developments in Cervical Cancer Screening and Prevention. Oxford, Blackwell Science, 1997, pp 200-202.
3. Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV.: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265.
4. Solomon D, Schiffman M, Tarrone R.: Comparison of three management strategies for patients with atypical squamous cells of undetermined significance. J Natl Cancer Inst 2001;93:293-299.
5. Ferlay J, Bray F, Pisani P, Parkin DM.: Globocan 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No 5, version 2.0. Lyon, IARC Press, 2004.
6. Pisani P, Parkin DM, Bray F, Ferlay J.: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
7. Aubin F, Pretet JL, Mougin C, et al.: Papillomavirus Humains. Biologie et Pathologie Tumorale. Paris, Editions TEC et DOC, 2003, pp 1-759.
8. Exbrayat C.: Col de l'utérus; in Remontet L, Buemi A, Velten M (eds): Evolution de l'Incidence et de la Mortalité par Cancer en France de 1978 à 2000. Paris, INVS, 2003, pp 107-112.
9. Rousseau A, Bohet P, Merlière J, Treppoz H, Heules-Bernin B, Ancelle-Park R.: Evaluation du dépistage organisé et du dépistage individuel du cancer du col de l'utérus: utilité des données de l'assurance maladie. Bull Epidémiol Hebdo 2002;19:81-83.
10. Weidmann C, Schaffer P, Hedelin G, Arveux P, Chaplain G, Exbrayat C, et al.: L'incidence du cancer du col de l'utérus régresse régulièrement en France. Bull Epidémiol Hebdo 1998;5:17-19.
11. Council of the European Union: Council recommendation of 2 December 2003 on cancer screening. Off J Eur Union 2003;327:34-38.
12. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
13. Franco EL, Rohan TE, Villa LL.: Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999;91:506-511.
14. IARC Working Group: Human Papillomavirus. IARC Monographs on the Evaluation of Carcinogenics Risk to Humans, vol 64. Lyon, International Agency for Research on Cancer, 1995.
15. Koutsky L.: Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
16. Schiffman M, Krüger-Kjaer S.: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Instit Monogr 2003;31:14-19.
17. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, et al.: Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-1423.
18. Rozendaal L, Westerga J, van der Linden JC, Walboomers JM, Voorhorst FJ, Risse EK, Boon ME, Meijer CJ.: PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol 2000;53:606-611.
19. Melkert PW, Hopman E, van den Brule AJ, Risse EK, van Diest PJ, Bleker OP, Helmerhorst T, Schipper ME, Meijer CJ, Walboomers JM.: Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993;53:919-923.
20. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S, IARC HPV Prevalence Surveys Study Group: Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991-998.
21. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM.: Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-1164.
22. GM Clifford, Smith JS, Aguado T, Franceschi S.: Comparison of HPV type distribution in highgrade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-105.
23. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-1079.
24. Castle PE, Solomon D, Schiffman M, Wheeler CM, The ALTS Group: Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005;97:1066-1071.
25. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB.: A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-1278.
26. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al.: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87: 1365-1371.
27. Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautiere JL, Carbillet JP, Kantelip B, Schaal JP, Mougin C.: Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106: 396-403.
28. Bory JP, Cucherousset J, Lorenzato M, Gabriel R, Quereux C, Birembaut P, Clavel C.: Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer 2002;102:519-525.
29. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al.: Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-3114.
30. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J.: Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-1628.
31. Wang SS, Hildesheim A.: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 2003;31:35-40.
32. Monsonego J.: Papillomavirus et cancer du col de l'utérus. Médecine/Sciences 1996;12:733-744.
33. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC, Nevins JR: Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 1992;89:4549-4553.
34. Thomas M, Matlashewski G, Pim D, Banks L.: Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene 1996;13:265-273.
35. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU, Proof of Principle Study Investigators: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-1651.
36. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6: 271-278.
37. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-1765.
38. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ.: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-285.
39. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E.: A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003;106:896-904.
40. Huang K, Lin S.: Nationwide vaccination: a success story in Taiwan. Vaccine 2000;18(suppl 1): S35-S38.
41. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E.: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-615.
42. Sanders GD, Taira AV.: Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003;9:37-48.
43. Kulasingam SL, Myers ER.: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-789.
44. Bozon M.: At what age do women and men have their first sexual intercourse? World comparisons and recent trends. Popul Soc 2003;391:1-4.
45. Anhang R, Wright TC Jr, Smock L, Goldie SJ.: Women's desired information about human papillomavirus. Cancer 2004;100:315-320.
46. Anhang R, Stryker JE, Wright TC Jr, Goldie SJ.: News media coverage of human papillomavirus. Cancer 2004;100:308-314.
47. Duffy SW, Tabar L, Chen HH, Holmqvist M, Yen MF, Abdsalah S, Epstein B, Frodis E, Ljungberg E, Hedborg-Melander C, Sundbom A, Tholin M, Wiege M, Akerlund A, Wu HM, Tung TS, Chiu YH, Chiu CP, Huang CC, Smith RA, Rosen M, Stenbeck M, Holmberg L.: The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 2002;95:458-469.
48. Feig SA.: Effect of service screening mammography on population mortality from breast carcinoma. Cancer 2002;95:451-457.
49. Monsonego J.: Spontaneous screening: benefits and limitations; in Franco E, Monsonego J (eds): New Developments in Cervical Cancer Screening and Prevention. Oxford, Blackwell Science, 1997, pp 220-240.
50. Monsonego J.: Enquête nationale sur le dépistage du cancer du col auprès des gynécologues. Gynécol Obstét Prat 1996;81:1-5.
51. Camatte S, Morice P, Pautier P, Lhommé C, Haie-Maider C, Duvillard P, Castaigne D.: Incidence et mortalité du cancer du col en France. Quelle relation avec le dépistage; in Blanc B (ed): Le dépistage du cancer du col de l'utérus. Paris, Springer, 2005, pp 35-45.
52. Garnett GP, Waddell HC.: Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol 2000;19:101-111.